Introduction {#S0001}
============

Hepatitis B virus (HBV) infection is a public health issue affecting approximately 257 million people worldwide.[@CIT0001] It was estimated that 80 million people were infected with HBV in China.[@CIT0002] Nucleos(t)ide analogues (NAs) can suppress viral replication by targeting the reverse transcriptase (RT) region of HBV. However, during long-term treatment, the drug resistance (DR) occurs due to variants in the RT region of HBV, leading to the failure of anti-HBV therapy.[@CIT0003],[@CIT0004]

Currently, there are four categories of RT region DR-related variants that have been reported, namely, primary variants, secondary/compensatory variants, putative resistant variants, and pretreatment variants.[@CIT0005] Primary and secondary RT variants have been widely investigated in chronic hepatitis B (CHB) patients treated with NAs.[@CIT0006]--[@CIT0010] Several previous studies have demonstrated that the classic DR variants also exist in chronic hepatitis B (CHB) patients not receiving NAs.[@CIT0011]--[@CIT0013] However, the results were quite discrepant among different areas and countries,[@CIT0005],[@CIT0014],[@CIT0015] and the prevalence of putative resistant variants and pretreatment variants among NAs-treated and untreated CHB patients were not well defined.

To date, the clinical factors affecting the incidence of potential DR-related variants in untreated CHB patients are still unclear. Therefore, the present study investigated the prevalence and clinical features of potential DR-related variants among Chinese CHB patients not receiving NAs.

Patients and Methods {#S0002}
====================

Patients {#S0002-S2001}
--------

We recruited 206 CHB patients from the Department of Infectious Diseases at Huzhou Central Hospital, China, between January 2016 and June 2018. CHB diagnosis was according to the Chinese consensus criteria suggested by the Guideline of Prevention and Treatment for Chronic Hepatitis B in 2015.[@CIT0002] None of the patients previously received NAs treatment at the time of blood sample collection. We confirmed that the study participants were not taking antiviral drugs by checking medical history records. The patients were excluded by other situations, including infected with hepatitis A virus, hepatitis C virus, hepatitis D virus, tuberculosis, or human immunodeficiency virus. The study was approved by the Ethics Committee of Huzhou Central Hospital in accordance with the ethical guidelines of the Declaration of Helsinki. All patients provided written informed consent. The serum samples were collected and stored at −70°C.

Detection of Serum Markers {#S0002-S2002}
--------------------------

HBsAg, anti-HBs, HBeAg, HBeAb and anti-HBc were measured using the Architect-i2000 system (Abbott Laboratories, USA). Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT) levels were measured by automated techniques (HITACHI 7600, Japan). Serum HBV-DNA was quantified by a commercial real-time polymerase chain reaction (PCR) detection kit (Liferiver, Shanghai, China), and the detection limit of the kit was 100 IU/mL. All these tests were performed in the Department of Laboratory Medicine of Huzhou Central Hospital.

Amplification of RT Region and DNA Sequencing {#S0002-S2003}
---------------------------------------------

Serum HBV-DNA was extracted from 200μL serum by High Pure Viral Nucleic Acid Kit (ROCHE, Switzerland) according to the manufacturer's protocol. The RT region of HBV was amplified by nest-PCR. The primers used in the first-round PCR were P1 (5ʹ-AGTCAGGAAGACAGCCTACTCC-3ʹ) and P2 (5ʹ-AGGTGAAGCGAAGTG CACAC-3ʹ)(nt2146-1596), the primers used in the second-round PCR were P3 (5ʹ-TTCCTGCTGGTGGCTCCAGTTC-3ʹ) and P4 (5ʹ-TTCCGCAGTATGGATCGGCAG-3ʹ) (nt 54--1278). The nested PCR was performed with the high-fidelity PrimeSTAR HS DNA Polymerase (Takara, Dalian, China). The PCR amplification conditions were applied as we previously described.[@CIT0016] The PCR products were purified using a QIAquick gel extraction kit (Qiagen, Hilden, Germany) and the bi-directional sequencing using ABI 3730xl genetic analyzer (Applied Biosystems, USA). All sequencing was performed by SunYa Applied Biotechnology Co. Ltd (Shanghai, China).

Genotyping and DR-Related Variants Analysis {#S0002-S2004}
-------------------------------------------

HBV genotyping was used online tool ([<http://www.ncbi.nih.gov/projects/genotyping/form.page.cgi>]{.ul}). The sequences results were translated into amino acid (AA) sequences and aligned to different genotype reference sequences through the multiple sequence alignment by MEGA 6.0 software. The potential DR-related variants in 42 positions within the RT region were analyzed.[@CIT0005],[@CIT0006]

Statistical Analysis {#S0002-S2005}
--------------------

Statistical analyses were performed using IBM SPSS 23.0 statistics software (IBM, New York, USA). Student's *t*-test was used for continuous variables, and Chi-square analysis or Fisher's exact test was used for categorical variables. The Mann--Whitney *U*-test was used to compare differences between continuous variables with non-normal distribution. Univariate and multivariate logistic regression analyses were used to investigate the factors that were associated with the RT variants. *P* values \<0.05 were considered statistically significant.

Results {#S0003}
=======

Characteristics of the CHB Patients {#S0003-S2001}
-----------------------------------

Among the 206 NAs-naïve CHB patients, 121 were infected with HBV genotype B and 85 were infected with HBV genotype C. HBeAg-positive rate was 57.8% (119/206). A comparison of the characteristics of the HBeAg-positive group and the HBeAg-negative group did not reveal any significant differences in gender or liver function markers (*P* \> 0.05). However, HBeAg-negative patients were older and had lower HBV-DNA loads than HBeAg-positive patients (*P* \< 0.05). Additionally, more patients were infected with HBV genotype C in the HBeAg-positive group compared with the HBeAg-negative group (*P* \< 0.05) ([Table 1](#T0001){ref-type="table"}).Table 1Demographic and Clinical Characteristics of CHB PatientsCharacteristicsHBeAg + (n=119)HBeAg -- (n=87)*P*Age(years), (mean±SD)32.7±12.242.3±11.2\<0.001Gender(male/female)85/3460/270.702HBV-DNA(log ~10~IU/mL), (mean±SD)6.9±1.55.2±1.4\<0.001HBV genotype (B/C)61/5860/270.011ALT(IU/L), median(range)76.8(15.0--2083.9)54.5(15.5--526.8)0.051AST(IU/L), median(range)50.8(13.7--1883.1)41.0(14.7--357.1)0.289ALP(IU/L), median(range)89.5(18.0--321.0)87.7(42.4--221.6)0.865GGT(IU/L), median(range)30.0(7.0--662.5)36.0(6.0--495.1)0.237TBil(IU/L), median(range)18.3(4.6--226.4)18.6(6.8--249.6)0.302[^1]

Prevalence of Potential DR-Related Variants in CHB Patients {#S0003-S2002}
-----------------------------------------------------------

In agreement with previous studies, eight sites were confirmed as genotype-dependent AA polymorphisms sites in the present study ([Table 2](#T0002){ref-type="table"}). These data revealed that the presence of asparagine or serine at rt53, isoleucine or leucine at rt91, asparagine or tyrosine at rt124, aspartic acid or asparagine at rt134, phenylalanine or tyrosine at rt221, isoleucine or valine at rt224, histidine or asparagine at rt238, and serine or cysteine at rt256 were closely linked to genotype B or genotype C, respectively (*P* \< 0 0.001). Therefore, the AA residue at each of the above sites was regarded as the consensus AA in B and C genotypes, respectively. The low frequencies of other AA residues at these sites were considered as variants in the present study.Table 2Genotype-Dependent AA Polymorphic Sites in This StudyGenotypert53rt91rt124NSA^a^D^a^H^a^I^a^ILNYD^a^H^a^B (n=121)112115113118109291C (n=85)085000077807807*P*\<0.001\<0.001\<0.001Genotypert134rt221DNA^a^E^a^H^a^S^a^FYC^a^H^a^N^a^B (n=121)229201060118111C (n=85)7731310832000*P*\<0.001\<0.001Genotypert224rt238rt256IVHND^a^CSG^a^B (n=121)411711920011011C (n=85)79618221273*P*\<0.001\<0.001\<0.001[^2]

We further analyzed 42 potential DR-related variant sites in the 206 NA-naïve CHB patients. RT variants were found in 42.7% (88/206) of CHB patients and included 29 sites. Primary and/or secondary DR variants were found in 7.3% (15/206) of patients, and included rtL80I/V, rtI169T, rtV173L, rtL180M, rtA181T/V, rtM204I/V, and rtN236T. Among these patients, seven were infected with genotype B and eight were infected with genotype C. The distributions of primary and/or secondary DR variants were not significantly different between genotype B and C (5.8% \[7/121\] vs 9.9% \[8/81\], *P* \> 0.05). The Putative DR-related variants and pretreatment variants were found in 38.8% (80/206) of CHB patients, which included 22 AA sites and 107 variants. The variation rates of putative DR-related variants and pretreatment variants were also not significantly different between genotypes B and C ([Table 3](#T0003){ref-type="table"}). Of note, the variants at rt53, rt82, rt221, rt233, rt237, and rt256 were specific for genotype B, and those at rt38, rt84, rt126, rt139, rt153, rt191, rt214, rt238, and rt242 were specific for genotype C ([Figure 1](#F0001){ref-type="fig"}).Table 3Prevalence of Potential DR-Related Variants of RT Region in CHB PatientsMutation CategoryType of VariantsGenotype B (n=121)Genotype C (n=85)*P*Number of Mutations (%)Primary resistance variantI169T2 (1.6)1 (1.2)0.779A181V/T1 (0.8)2 (2.4)0.570M204I/V4 (3.2)4 (4.8)0.720N236T1 (0.8)1 (1.2)1.000Secondary/compensatory variantL80I/V3 (2.4)2 (2.4)1.000V173L0 (0.0)2 (2.4)0.169L180M1 (0.8)3 (3.6)0.308Putative DR variantN53A/D/H/I8 (6.4)0 (0.0)0.022L82Q1 (0.8)0 (0.0)1.000V84I0 (0.0)1 (1.2)0.413H126Q/Y0 (0.0)2 (2.4)0.169T128A/D/I/N/P5 (4.0)6 (7.2)0.367N139D0 (0.0)1 (1.2)0.413R153Q0 (0.0)1 (1.2)0.413V191I0 (0.0)2 (2.4)0.169V207I/L/M5 (6.0)3 (3.6)1.000S213T7 (5.6)2 (2.4)0.312V214A0 (0.0)1 (1.2)0.413Q215H2 (1.6)1 (1.2)0.779Y221C/N/H3 (2.4)0 (0.0)0.269L229V/M3 (2.4)2 (2.4)1.000I233V1 (0.8)0 (0.0)1.000P237S1 (0.8)0 (0.0)1.000N238D0 (0.0)2 (2.4)0.169S/C256G11 (8.8)0 (0.0)0.003Pretreatment variantT38A0 (0.0)1 (1.2)0.413N/Y124D/H10 (8.0)7 (8.4)0.994D/N134A/E/H/S7 (5.6)5 (6.0)1.000N139K2 (1.6)3 (3.6)0.405R242S0 (0.0)1 (1.2)0.413 Figure 1RT variants in genotype B and C HBV infected patients.**Abbreviations:** RT, reverse transcriptase; CHB, chronic hepatitis B; HBV, hepatitis B virus.

Because the hepatitis B surface antigen gene overlaps with the RT gene, we analyzed this region in detail and found that the mutations at rt134, rt139, and rt153 sites overlapped with the "a" determinant of the S gene. In the present study, the rt134 and rt153 variants led to the concomitant occurrence of "a" determinant mutations, including sT126A (n=5), sT126S (n=2), sT126N (n=1), and sG145R (n=1).

Variant Site Distribution and Frequency in Different Sections of the RT Region {#S0003-S2003}
------------------------------------------------------------------------------

The RT region consists of functional domains (G, F, A, B, C, D, and E) and interdomains (F-A, A-B, B-C, C-D and D-E).[@CIT0005] Our results showed that all six sites (6/6, 100%) in A-B interdomain contained variants, and the variation rate was higher than those of the functional domains (15/22, 68.2%) and non-A-B interdomains (8/14, 57.1%), but no statistically significant differences were observed (*P* \> 0.05). Furthermore, the variation frequency was also significantly higher (3.96%) in the A-B interdomain than in the functional domains (1.17%) and non-A-B interdomains (1.11%) (*P* \< 0.01) ([Table 4](#T0004){ref-type="table"}). However, no significant difference was showed in the functional domains, and the A-B interdomains between genotype B and C with respect to the number and frequencies of variants (*P* \> 0.05). The variation frequency of genotype C in the non-A-B interdomains was higher than that of genotype B (*P* \< 0.05).Table 4Variation Distribution and Frequency in Different RT RegionsRegion in RT(Sites Studied in This Study)Number of Variation Sites (%)*P*Frequency (%)*P*Domain(22)Genotype B11/22(50)1.000^a^31/4532 (0. 68%)0.215^a^Genotype C11/22(50)22/4532 (0.48%)Total15/22(68.2)0.288^b^53/4532 (1.17%)\<0.001^c^A-B interdomain(6)Genotype B4/6(66.7)0.455^a^24/1236 (1.94%)0.885^a^Genotype C6/6(100)25/1236 (2.02%)Total6/6(100.0)0.115^b^49/1236 (3.96%)\<0.001^c^Non-A-B interdomain (14)Genotype B5/14(35.7)0.699^a^9/2884(0.31%)0.013^a^Genotype C6/14(42.8)23/2884 (0.79%)Total8/14(57.1)0.501^b^32/2884(1.11%)0.813^c^[^3]

Relationship Between Potential DR-Related Variants and Clinical Features {#S0003-S2004}
------------------------------------------------------------------------

The characteristics were compared between CHB patients with and without RT variants. The average age of patients with RT variants was older than that of patients without RT variants (*P* \< 0.05). The mean HBV-DNA loads were significantly lower in patients with RT variants than in patients without RT variants (*P* \< 0.05) ([Figure 2A](#F0002){ref-type="fig"}). However, this difference was not observed between patients with variants and without variants when the patients were divided into HBeAg-positive and HBeAg-negative subgroups (*P* \> 0.05) ([Figure 2B](#F0002){ref-type="fig"} and [C](#F0002){ref-type="fig"}). The average ALT levels of patients with variants were lower than those in patients without variants (*P* \< 0.05). There were no significant differences in gender; AST, ALP, GGT, and TBil levels; HBeAg status; and genotype distribution between patients with and without DR-related variants ([Table 5](#T0005){ref-type="table"}).Table 5Clinical Features of CHB Patients with and without Potential DR-Related VariantsCharacteristicsPatients without Variants (n=118)Patients with Variants (n=88)*P*Gender(male/female)80/3865/230.345Age(years), (mean±SD)35.2±12.938.9±12.10.014HBeAg status(+/-)75/4344/440.051HBV DNA(log ~10~IU/mL), (mean±SD)6.47±1.685.84±1.630.007HBV genotype(B/C)70/4851/370.884ALT(IU/L), median(range)81.4(15.0--2083.9)52.8(18.2--992.8)0.041AST(IU/L), median(range)52.7(14.7--1883.1)39.3(13.7--719.0)0.070ALP(IU/L), median(range)92.5(30--220.9)83.3(18.0--321.0)0.154GGT(IU/L), median(range)30.2(6.0--495.1)31.8(7.0--662.5)0.527TBil(IU/L), median(range)18.4(4.6--226.4)18.6(6.3--249.6)0.728[^4] Figure 2HBV-DNA loads in untreated CHB patients with or without RT variants. (**A**) All patients (**B**) Patients with HBeAg positive (**C**) Patients with HBeAg negative.**Abbreviations:** HBV, hepatitis B virus; CHB, chronic hepatitis B; RT, reverse transcriptase; HBeAg, hepatitis B virus e antigen.

Further analysis revealed no significant differences in gender, age, HBeAg status, and liver function markers (including ALT, AST, ALP, GGT, and TBil) between patients with single and multiple variants (*P* \> 0.05) ([Table 6](#T0006){ref-type="table"}). Univariate logistic regression analysis results revealed that age (≥35 years old) and HBV-DNA load (\<10^6^ IU/mL) were associated with the potential DR-related variants *(P* \< 0.05) ([Table 7](#T0007){ref-type="table"}). No relationship was found between the other factors (gender, HBeAg status, genotype, and liver function markers) and the DR-related variants. Furthermore, multivariate logistic regression analysis showed that the HBV-DNA load (\<10^6^ IU/mL) was an independent factor associated with the potential DR-related variants in the untreated CHB patients *(P* \< 0.05) ([Table 7](#T0007){ref-type="table"}).Table 6Comparison of Clinical Characteristics in CHB Patients with Different Number of Potential DR-Related VariantsCharacteristicsNumber of RT Variants*P*Single VariantMultiple Variants (≥2)Gender(male/female)44/1221/110.184Age (years)39.1±12.338.5±12.10.827HBeAg status(+/-)24/3220/120.076HBV DNA(log ~10~IU/mL), (mean±SD)5.85±1.745.81±1.430.922HBV genotype(B/C)33/2318/140.807ALT(IU/L), median(range)52.5(18.6--992.8)44.2(18.2--887.5)0.195AST(IU/L), median(range)41.4(13.7--636.9)35.8(14.8--719.0)0.149ALP(IU/L), median(range)84.8(18.0--221.6)82.8(46.9--321.0)0.859GGT(IU/L), median(range)32.8(7.0--662.5)31.5(8.8--191.1)0.374TBil, (IU/L), median(range)18.4(7.2--157.9)19.6(6.3--249.6)0.469[^5] Table 7Univariate and Multivariate Logistic Analyses of Factors for Potential DR-Related VariantsFactorUnivariate AnalysisMultivariate AnalysisOR95% CI*P*OR95% CI*P*LowerUpperLowerUpperAge\<35yr11≥35yr1.0241.0011.0470.0371.6610.8863.1120.114HBeAgNegative11Positive0.5730.3271.0050.0520.9160.4701.7880.798HBV DNA\<10^6^IU/mL11≥10^6^IU/mL0.7940.6700.9410.0080.4520.2570.7940.006ALT\<80IU/L11≥80 IU/L0.9990.9971.0000.1050.7060.3911.2720.246[^6]

Discussion {#S0004}
==========

The prevalence of potential DR-related variants in the HBV RT region in NAs-untreated CHB patients has been reported in several previous studies but the results are controversial.[@CIT0006],[@CIT0007],[@CIT0014],[@CIT0017],[@CIT0018] In the present study, potential DR-related variants were detected in 42.7% (88/206) of untreated CHB patients, and primary and secondary DR variants were found in 7.3% (15/206) patients. Several studies have reported that the prevalence rate of primary and secondary DR variants was low or even zero in untreated patients.[@CIT0007],[@CIT0010],[@CIT0014],[@CIT0017] However, the present study revealed that primary and secondary DR variants existed in a considerable proportion of NAs-untreated CHB patients. A study in central China reported that variants associated with DR were detected in 8.9% of untreated patients.[@CIT0013] Another study recently reported DR variants in 6% of Brazilian treatment-naïve CHB patients,[@CIT0018] and a meta-analysis showed that the pooled incidence of naturally resistant variants in China was higher than that in other countries (8.00% vs 1.88%).[@CIT0019] Overall, the incidence of DR variants was closely related to the geographical distribution and epidemic situation of the HBV infection. For instance, the prevalence rate of DR variants in China was higher (8.00%) because HBV infection is highly endemic to China. However, in Europe, the prevalence rate of DR variants was lower (2.53%) due to low levels of endemic HBV infection.[@CIT0019] Furthermore, some variants were related to DR to entecavir and tenofovir disoproxil fumarate, such as rtI169T, rtl180M, rtM204I/V, rtH126Y and rtD134E, which have been previously reported,[@CIT0002],[@CIT0021] and were also found in the present study. Considering the impact of potential DR variants on treatment efficacy, it is crucial to detect the DR-related variants prior to administering anti-HBV treatment.

Agree with previous studies,[@CIT0005] eight AA polymorphic positions (rt53, rt91, rt124, rt134, rt221, rt224, rt238 and rt256) were identified for genotype B and C. We further analyzed the AA polymorphic positions in the RT region for genotype A to I using an online tool ([<https://hivdb.stanford.edu/HBV/DB/cgi-bin/MutPrevByGenotypeRxHBV.cgi>]{.ul}). The results showed that these eight sites were genotype-dependent AA polymorphic positions. Additionally, another study reported that AA polymorphic positions showed discrepancies in different areas in China.[@CIT0015] These data indicated that the definition of genotype variants needs to take into account the reference sequences of different genotypes in different areas and the consensus sequence derived from local HBV isolates. Moreover, researchers have also suggested that some AA polymorphic positions could contribute to decreased viral replication and affect drug treatment outcomes.[@CIT0005],[@CIT0008] Thus, the genotype-dependent polymorphism sites could influence the effect of antiviral treatment by regulating virus replication and/or fitness.

The RT region is separated into functional domains (G, F A, B, C, D and E) and interdomains (F-A, A-B, B-C, C-D and D-E).[@CIT0005],[@CIT0022] Previous studies have shown that the variation frequency in the A-B interdomain was higher than that in the other regions,[@CIT0005],[@CIT0023]--[@CIT0026] and this was also observed in the present study. Moreover, when genotype B or C was analyzed separately, this difference still existed. However, there was no difference in the variation frequency between genotypes B and C in the functional domains or A-B interdomain. Overall, the A-B interdomain showed the highest frequency of variation in the RT region in NAs-naïve CHB patients. Notably, there was a significant difference in the variation frequency between genotype B and C in non-A-B interdomains. An Indonesian study also showed that potential DR-related variants were more frequent in genotype C than in genotype B.[@CIT0024] Hence, the driving factors and the mechanism of RT variations among different genotypes are worth further study.

An interesting finding was that some variants appeared specific to particular genotypes. Some of these positions had been reported previously, but others (rt82, rt214, and rt242) were not found in the corresponding genotype from previous studies.[@CIT0005],[@CIT0015] The rt242 variant was only found in genotype B in a previous study[@CIT0005] but was found only in genotype C in our study. Therefore, we speculated that different genotypes possessed different RT variants due to differences in evolutionary characteristics. Thus, the relationship between the genetic diversity of genotypes and the distribution of sites of potential DR-related variants requires further elucidation.

Until now, the correlation between potential DR-related variants and clinical characteristics among NAs--naïve patients remained unclear. Previous studies did not find any significant association between the presence of potential DR-related variants and the gender, age, HBeAg status, HBV-DNA loads, or ALT and AST levels.[@CIT0005],[@CIT0019] Recently, a study in China showed that the natural RT variants were associated with low HBV-DNA loads in HBeAg-negative patients.[@CIT0014] Our study compared the clinical characteristics between CHB patients with and without potential DR variants, and found differences in age, HBV-DNA loads, and ALT levels ([Table 5](#T0005){ref-type="table"}). Several studies have showed that potential DR variants were associated with HBeAg-negative status.[@CIT0010],[@CIT0013] In the present study, the negative rate of HBeAg in patients with DR-related variants was higher than that in patients without DR-related variants (50% vs 36.4%), but a significant difference was not observed. The HBeAg-negative status may lead to greater host immune pressure against HBV, which could result in the generation of more variants due to the selection pressures. Another previous study showed that some naturally occurring AA substitutions in the RT region might influence the serum HBV-DNA load in HBeAg-positive CHB patients with sub-genotype B2.[@CIT0027] Therefore, the impact of HBeAg status on the RT variants deserves further study. A recent review also suggested that low HBV-DNA loads were associated with potential DR variants.[@CIT0028] In the present study, further logistic regression analysis showed that the lower HBV-DNA load was an independent factor that was related to patients with potential DR-related variants ([Figure 1](#F0001){ref-type="fig"}, [Table 7](#T0007){ref-type="table"}). This data was consistent with several other previous studies, indicating that naturally occurring RT variants were associated with decreased HBV-DNA loads.[@CIT0017],[@CIT0026],[@CIT0029] The reason may be that HBV replication is often impaired by the RT variants, which decreases the activity of polymerase. Although another study indicated that patients with multiple RT variants showed decreased HBV-DNA loads compared with patients with a single RT variant,[@CIT0029] there was no difference in HBV-DNA loads and other clinical factors (gender, age, genotype, HBeAg, ALT, and AST levels) between the single variant and the multiple variants subgroups, implying that certain single RT variants played a crucial role in viral replication. It is also worth noting that no classical primary and secondary variants were found in several previous studies,[@CIT0014],[@CIT0029] which might have influenced the results of the analysis. Taken together, the key roles of some RT variants in viral replication and fitness require further elucidation.

Recently, the application of next-generation sequencing (NGS) was gradually introduced for the investigation of DR variants in CHB patients.[@CIT0030]--[@CIT0032] This method has higher sensitivity than direct sequencing and can detect minor pre-existing DR-related variants that are undetectable using Sanger sequencing.[@CIT0033]--[@CIT0036] A recent study demonstrated that NGS was more suitable for detecting low rate DR variants in untreated patients than Sanger sequencing.[@CIT0015] However, because the NGS technology is more costly and requires a highly technical platform in comparison with Sanger sequencing, we used Sanger sequencing to analyze the potential DR-related variants in this study. Thus, the actual prevalence rate of potential DR related variants in untreated patients might be higher than our results. Nonetheless, the current study provides a rationale for further surveillance of the prevalence of potential DR-related variants using NGS.

Conclusions {#S0005}
===========

In summary, the frequency of potential DR-related variants was relatively high and their patterns were complex and diverse among NAs-naive CHB patients, which might contribute to lower HBV-DNA loads. The genotype B and C showed preferred RT variation sites. Further large-scale investigations are needed to clarify the clinical significance and evolution characteristics of potential DR-related variants in the RT region of HBV in untreated CHB patients.
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[^1]: **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; TBil, total bilirubin; SD, standard deviation.

[^2]: **Notes:** ^a^Described as RT variants in this study.

    **Abbreviations:** A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine H, histidine; I, isoleucine; L, leucine; N, asparagine; S, serine; V, valine; Y, tyrosine.

[^3]: **Notes:** ^a^Comparison of number of variation sites and frequency in different RT sections between B-genotype and C genotype. ^b^ Comparison of number of variation sites among different RT region were as follow: Domain vs A-B interdomain, *P*=0.288; Domain vs Non-A-B interdomain, *P*=0.501; A-B interdomain vs Non-A-B interdomain, *P*=0.115. ^c^ Comparison of variation frequency among different RT region were as follow: Domain vs A-B interdomain, *P*\<0.001; Domain vs Non-A-B interdomain, *P*=0.813; A-B interdomain vs Non-A-B interdomain, *P*\<0.001. For example, the calculation method of variation frequency was as follows: 31 mutations/(22 studies sites×206 isolates)\*100%=31/4532×100%=0.68%

[^4]: **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; TBil, total bilirubin; SD, standard deviation.

[^5]: **Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; TBil, total bilirubin; SD, standard deviation.

[^6]: **Note:** *P*-value by logistic regression analysis.

    **Abbreviations:** OR, odds ratio; CI, confidence interval.
